Published in Proc Natl Acad Sci U S A on September 04, 2009
Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci (2011) 2.16
Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A (2010) 2.02
Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta (2012) 1.74
Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry (2010) 1.72
Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region. Biochem J (2010) 1.66
Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech (2012) 1.59
Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal (2010) 1.27
Normal and Friedreich ataxia cells express different isoforms of frataxin with complementary roles in iron-sulfur cluster assembly. J Biol Chem (2010) 1.23
Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia. Nucleic Acids Res (2011) 1.16
Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol (2013) 1.15
Iron-sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery. Biochim Biophys Acta (2014) 1.12
Molecular details of the yeast frataxin-Isu1 interaction during mitochondrial Fe-S cluster assembly. Biochemistry (2010) 1.10
Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia. Mol Cell Neurosci (2012) 1.08
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A (2012) 0.97
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. Hum Mol Genet (2011) 0.94
Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med (2016) 0.93
Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development. Pediatr Cardiol (2011) 0.93
Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front Pharmacol (2014) 0.91
Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol (2012) 0.91
Autophagy induction extends lifespan and reduces lipid content in response to frataxin silencing in C. elegans. Exp Gerontol (2012) 0.90
Genome-wide expression patterns in physiological cardiac hypertrophy. BMC Genomics (2010) 0.89
Current and emerging treatment options in the management of Friedreich ataxia. Neuropsychiatr Dis Treat (2010) 0.89
Relation of cytosolic iron excess to cardiomyopathy of Friedreich's ataxia. Am J Cardiol (2012) 0.89
Iron and copper in mitochondrial diseases. Cell Metab (2013) 0.88
Frataxin participates to the hypoxia-induced response in tumors. Cell Death Dis (2011) 0.85
Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia. Br J Pharmacol (2014) 0.83
Cerebellar pathology in Friedreich's ataxia: atrophied dentate nuclei with normal iron content. Neuroimage Clin (2014) 0.82
Mitochondrial metals as a potential therapeutic target in neurodegeneration. Br J Pharmacol (2014) 0.82
Reduction of mitoferrin results in abnormal development and extended lifespan in Caenorhabditis elegans. PLoS One (2012) 0.81
A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype. Neurogenetics (2011) 0.80
Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells. Pflugers Arch (2013) 0.80
The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas. Eur J Med Res (2014) 0.80
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol (2014) 0.78
Transition metals and mitochondrial metabolism in the heart. J Mol Cell Cardiol (2012) 0.77
mRNA regulation of cardiac iron transporters and ferritin subunits in a mouse model of iron overload. Exp Hematol (2014) 0.76
Mitochondrial iron overload: causes and consequences. Curr Opin Genet Dev (2016) 0.76
Iron homeostasis in peripheral nervous system, still a black box? Antioxid Redox Signal (2014) 0.75
Mössbauer Spectra of Mouse Hearts Reveal Age-dependent Changes in Mitochondrial and Ferritin Iron Levels. J Biol Chem (2017) 0.75
Revisiting Metal Toxicity in Neurodegenerative Diseases and Stroke: Therapeutic Potential. Neurol Res Ther (2015) 0.75
Cardiac involvement in hereditary ataxias. J Child Neurol (2012) 0.75
"Pumping iron"-how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch (2017) 0.75
Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective. PLoS Comput Biol (2017) 0.75
Cells lacking pfh1, a fission yeast homolog of mammalian frataxin protein, display constitutive activation of the iron starvation response. J Biol Chem (2012) 0.75
Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model. JCI Insight (2017) 0.75
The Iron Chaperone Poly (rC)-binding Protein 2 Forms a Metabolon with the Heme Oxygenase 1/Cytochrome P450 Reductase Complex for Heme Catabolism and Iron Transfer. J Biol Chem (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A (2000) 18.42
Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev (2008) 4.87
Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet (1997) 4.26
Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science (1997) 3.94
Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet (2001) 3.10
The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet (2002) 2.32
An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep (2003) 2.29
Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00
Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum Mol Genet (2003) 1.99
Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet (1997) 1.79
A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem (2001) 1.69
The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol (2009) 1.68
Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet (2004) 1.66
Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66
Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood (2004) 1.62
Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program (2006) 1.57
Adrenodoxin reductase homolog (Arh1p) of yeast mitochondria required for iron homeostasis. J Biol Chem (2001) 1.57
Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem (2001) 1.56
Targeting of a human iron-sulfur cluster assembly enzyme, nifs, to different subcellular compartments is regulated through alternative AUG utilization. Mol Cell (1998) 1.56
Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett (1999) 1.52
The mitochondrial proteins Ssq1 and Jac1 are required for the assembly of iron sulfur clusters in mitochondria. J Mol Biol (2001) 1.52
Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet (2008) 1.30
Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria. J Biol Chem (2006) 1.29
Frataxin and mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for heme synthesis. J Biol Chem (2005) 1.23
Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. Hum Mol Genet (2005) 1.23
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22
Involvement of mitochondrial ferredoxin and Cox15p in hydroxylation of heme O. FEBS Lett (2001) 1.17
A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet (2005) 1.16
Biogenesis of iron-sulfur proteins in eukaryotes: components, mechanism and pathology. Mitochondrion (2002) 1.12
Human frataxin: iron and ferrochelatase binding surface. Chem Commun (Camb) (2007) 1.00
Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats. Hepatology (1994) 0.96
The anemia of "haemoglobin-deficit" (hbd/hbd) mice is caused by a defect in transferrin cycling. Exp Hematol (2006) 0.94
Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor or heme synthesis. Biochim Biophys Acta (1982) 0.92
The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis (2006) 0.90
Abnormal iron deposition associated with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain. J Neuropathol Exp Neurol (1998) 0.85
The effects of inhibition of heme synthesis on the intracellular localization of iron in rat reticulocytes. Biochim Biophys Acta (1989) 0.81
Iron overload in human disease. N Engl J Med (2012) 3.77
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22
Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood (2004) 2.12
Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A (2010) 2.02
Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00
Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology (2002) 1.97
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96
The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta (2002) 1.86
New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr (2004) 1.71
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood (2004) 1.67
Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66
Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood (2004) 1.62
Direct interorganellar transfer of iron from endosome to mitochondrion. Blood (2007) 1.59
Heme oxygenase 1 is expressed in murine erythroid cells where it controls the level of regulatory heme. Blood (2014) 1.59
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis (2006) 1.49
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One (2013) 1.46
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43
Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol (2008) 1.43
The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol (2002) 1.40
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol (2003) 1.38
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38
The long history of iron in the Universe and in health and disease. Biochim Biophys Acta (2011) 1.33
Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem (2006) 1.30
Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res (2003) 1.30
Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 1.29
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res (2006) 1.28
Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res (2011) 1.28
Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A (2009) 1.25
Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25
Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol (2008) 1.24
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21
Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood (2009) 1.18
Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallogr C (2003) 1.17
Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem (2005) 1.17
The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis (2011) 1.17
S-nitrosylation of IRP2 regulates its stability via the ubiquitin-proteasome pathway. Mol Cell Biol (2004) 1.16
Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal (2012) 1.16
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood (2006) 1.15
Nitrogen monoxide-mediated control of ferritin synthesis: implications for macrophage iron homeostasis. Proc Natl Acad Sci U S A (2002) 1.14
Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13
The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J (2009) 1.12
Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol (2004) 1.11
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol (2011) 1.11
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal (2012) 1.09
The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS Lett (2002) 1.09
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol (2012) 1.08
Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol (2011) 1.07
Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab (2013) 1.06
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci U S A (2006) 1.06
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem (2010) 1.05
Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol (2009) 1.05
Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood (2004) 1.03
Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2009) 1.03
Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem (2009) 1.03
In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood (2006) 1.02
The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta (2010) 1.02
P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem (2013) 1.01
Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochim Biophys Acta (2013) 1.00
Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorg Med Chem Lett (2012) 0.99
Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorg Med Chem Lett (2012) 0.99
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. J Med Chem (2007) 0.98
Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem (2011) 0.98
Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. Biochem J (2003) 0.98
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A (2012) 0.97
Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem (2009) 0.96
Investigating biological activity spectrum for novel quinoline analogues. Bioorg Med Chem (2006) 0.96
Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol Pharmacol (2012) 0.96
Nramp1 equips macrophages for efficient iron recycling. Exp Hematol (2008) 0.96
Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J Biol Inorg Chem (2003) 0.95
The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol (2011) 0.95